Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD ...Middle East

AUSTIN, Texas, April 11, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today shared additional data from the PEACE Phase 3...

Hence then, the article about aeglea biotherapeutics presents additional data from peace phase 3 study of pegzilarginase for the treatment of arginase 1 deficiency at simd was published today ( Monday 11/04/2022 - 11:49 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD )

Also on site :

• Macy’s Has a 12-Piece Lenox Scalloped Dinnerware Set for 59% Off That's Perfect for Hosting Spring Events
• This Spring, Divest From Clutter to Reclaim Personal Productivity Like a Boss .. PYMNTS.com
• This Can't Miss Scenic Spot Just Under an Hour from Vegas Will Have You Feeling Like You're in Another World